UK-based AI biotechnology company Exscientia partnered with one of Europe’s largest university hospitals, Charité, to use Exscientia’s AI-based precision medicine platform in the treatment of hematological cancers.
Charité will assess Exscientia’s precision medicine platform capabilities in identifying effective treatments for hematological cancer patients. This involves testing various drugs, including those that have not yet been approved for this condition, on patient samples to determine their response.
The partnership will build on the findings of the EXALT-1 study. This study showed that Exscientia’s drug testing platform, which provides personalized treatment recommendations, resulted in significantly better outcomes for patients with advanced hematologic cancer compared to the treatment chosen by physicians. Charité will also create a biobank of cryopreserved blood, bone marrow, and lymph node tissues (which includes live human tissue samples) to assist in the advancement of technology and preclinical research projects at both companies.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.